• identification and treatment of underlying etiological factors implicated in the development of HFpEF
• identification and treatment of comorbid conditions which may exacerbate the HF syndrome; (3) control of symptoms
• realization of clinically meaningful cardiovascular endpoints such as HF hospitalization and mortality.

There remains a paucity of clinical trial data regarding specific pharmacological therapy in the HFpEF population at this time. Comorbid conditions including other chronic medical diseases are common in the HFpEF population and frequently implicated as triggers for HF decompensation, thus optimal management of these coexistent disorders, including pharmacological and non-pharmacological therapies, should be aggressively pursued.